New International Life Science Anti-Corruption Compliance Considerations: Measuring and Testing Top-Down Effectiveness and Individual/Corporate Transparency of Compliance Controls

May 10, 2024 9:00am

Ash Aggarwal
Principal, Global Commercial Compliance
IQVIA (UK)

Ciara Farrell
Vice President, Associate General Counsel and Global Head of Ethics and Compliance
ICON Plc (Ireland)

Nicole Willms
Partner
Pohlmann & Company (Germany)

Leon C. G. Liu
Partner, Head of Government Enforcement and Investigations
JunHe LLP (China)

Amid increased global enforcement postures and compliance program standards, it is critical that multinational life sciences companies ensure that their programs are pressure-tested (and re-tested) toward mitigating individual/corporate liability risks and strengthening corporate culture.

  • Global anticorruption enforcement efforts and comparisons to the FCPA:
    • The UK Economic Crime and Corporate Transparency Act
    • EU Anti-Corruption Directive
  • The interplay of GDPR with anti-corruption compliance efforts
  • Assessing compliance controls in an era of remote and hybrid work
  • Where do global anti-corruption efforts intersect with data privacy compliance requirements?
  • How to evaluate your training and controls by means other than audits
  • Ensuring that your program is aligned on paper and in practice